- Home
- TARS vs ITGR Comparison
TARS vs ITGR Comparison
Compare TARS & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | ITGR |
|---|---|---|
| Founded | 2016 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TARS | ITGR |
|---|---|---|
| Price | $63.52 | $83.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $89.00 | ★ $91.14 |
| AVG Volume (30 Days) | ★ 446.1K | 417.2K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ 0.48 |
| Revenue | $451,360,000.00 | ★ $1,853,637,000.00 |
| Revenue This Year | $56.43 | $1.69 |
| Revenue Next Year | $30.19 | $6.53 |
| P/E Ratio | ★ N/A | $30.75 |
| Revenue Growth | ★ 146.71 | 7.98 |
| 52 Week Low | $38.51 | $62.00 |
| 52 Week High | $85.25 | $126.00 |
Technical Indicators
Market Signals| Indicator | TARS | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 44.44 |
| Support Level | $61.24 | $82.58 |
| Resistance Level | $67.70 | $89.04 |
| Average True Range (ATR) | 3.19 | 3.47 |
| MACD | -0.40 | -0.29 |
| Stochastic Oscillator | 25.54 | 47.72 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.